Guggenheim Issues Positive Forecast for Metsera (NASDAQ:MTSR) Stock Price

Metsera (NASDAQ:MTSR) had its price objective raised by Guggenheim from $56.00 to $62.00 in a research report report published on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other brokerages also recently issued reports on MTSR. Bank of America assumed coverage on Metsera in a research note on Tuesday, February 25th. They issued a “buy” rating and a $38.00 price objective for the company. Cantor Fitzgerald assumed coverage on Metsera in a research note on Tuesday, February 25th. They issued an “overweight” rating for the company. Finally, Evercore ISI assumed coverage on Metsera in a research note on Tuesday, February 25th. They issued an “outperform” rating for the company.

Metsera Price Performance

Shares of NASDAQ MTSR opened at $35.10 on Tuesday. Metsera has a 12 month low of $12.30 and a 12 month high of $37.99. The company’s fifty day moving average is $23.40.

Metsera (NASDAQ:MTSR) last announced its earnings results on Monday, May 12th. The company reported ($1.03) EPS for the quarter.

Institutional Investors Weigh In On Metsera

Hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp acquired a new position in Metsera in the 1st quarter worth about $884,000. New York State Common Retirement Fund acquired a new position in Metsera in the 1st quarter worth about $131,000. Alphabet Inc. acquired a new position in Metsera in the 1st quarter worth about $135,059,000. Massachusetts Financial Services Co. MA acquired a new position in Metsera in the 1st quarter worth about $13,111,000. Finally, Jennison Associates LLC acquired a new position in Metsera in the 1st quarter worth about $9,679,000.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.